Bagsvaerd, Denmark — Novo Nordisk has launched the Wegovy pill for weight loss in the United States, marking a significant milestone in obesity treatment. The company announced the rollout will begin Monday, following recent FDA approval of the first-ever oral GLP-1 treatment designed for weight management.
The Wegovy pill is competitively priced, with monthly costs ranging from $149 to $299, depending on the dosage. This pricing strategy aims to alleviate some of the financial barriers associated with existing weight loss therapies, particularly the more expensive weekly injections that have dominated the market.
Pharmacies across the country, including CVS and Costco, will stock the initial dose of 1.5 milligrams, while higher doses are expected to become available later this week. The broader availability means that many of the over 100 million Americans affected by obesity could access this new treatment option more easily.
Novo Nordisk’s announcement also highlights an agreement with a direct-to-consumer website affiliated with former President Donald Trump. This collaboration aims to offer cash-paying patients the starting dose at a fixed price of $149 monthly on the new platform, scheduled to launch in January.
The launch of Wegovy comes at a time when other weight loss medications, particularly injectable options from Novo Nordisk and Eli Lilly, are significantly more expensive, sometimes exceeding $1,000 monthly. These injections, while effective, pose affordability challenges for many, particularly those without insurance coverage. In comparison, patients with insurance can expect to pay as little as $25 monthly for the new oral medication.
Both companies are looking to the oral medication market as a critical battleground; analysts suggest it could grow to be worth around $100 billion by the 2030s. Goldman Sachs has projected that these oral treatments could capture nearly a quarter of that market share. As the first key player in this emerging segment, Novo Nordisk’s launch potentially positions the company for significant growth.
In addition to weight loss, Wegovy has been approved to help reduce major cardiovascular risks among individuals with obesity and pre-existing heart conditions. The pill, which mimics the gut hormone GLP-1 to curb appetite, is expected to address multiple health challenges associated with obesity.
In clinical trials involving over 300 participants, those taking the highest dose of the Wegovy pill demonstrated an average weight loss of 16.6% over 64 weeks. This level of effectiveness places it ahead of some competitors’ oral options, which do not require eating restrictions.
Ultimately, the anticipation surrounding the Wegovy pill underscores a larger shift in how obesity is treated in the U.S. Novo Nordisk believes this development will change the landscape of weight management, making effective treatment more accessible to those in need.
